Loading cancer entity…
Loading cancer entity…
Clinical trials
972 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (145)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03091933 | Antiminor Histocompatibility Complex (MiHA) T Cells for Patients With Relapsed Hematologic Malignancies Following Matched HSCT (Guided Lymphocyte Immunopeptide Derived Expansion)(GLIDE) | unknown | Phase 1 / Phase 2 | 20 | Ciusss de L'Est de l'Île de MontréalOTHER | 1 | Dec 6, 2017 | clinicaltrials |
| NCT00556452 | Study of Stem Cell Transplantation for Hematologic Malignancies Using Clofarabine and Busulfan Regimen | completed | Phase 1 / Phase 2 | 46 | University of Michigan Rogel Cancer CenterOTHER |
| 1 |
| Dec 5, 2017 |
| clinicaltrials |
| NCT01343368 | Preservation of Ovarian Function After Hematopoietic Cell Transplant | terminated | Phase 2 | 19 | Masonic Cancer Center, University of MinnesotaOTHER | 1 | Dec 5, 2017 | clinicaltrials |
| NCT01460940 | A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma | completed | Phase 2 | 24 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Nov 14, 2017 | clinicaltrials |
| NCT00540007 | Lenalidomide in Relapsed or Refractory Classical Hodgkin Lymphoma | completed | Phase 2 | 80 | Washington University School of MedicineOTHER | 1 | Nov 6, 2017 | clinicaltrials |
| NCT00722865 | Avastin (Bevacizumab) Plus Adriamycin, Bleomycin, Vinblastine and Dacarbazine (ABVD) for Advanced Stage Hodgkin Lymphoma | terminated | Phase 2 | 25 | Massachusetts General HospitalOTHER | 1 | Oct 18, 2017 | clinicaltrials |
| NCT03244930 | Low Dose Plerixafor Plus G-CSF in Mobilizing Stem Cells for Autologous Peripheral Blood Transplantation | unknown | Phase 2 | 20 | Hospital Universitario Dr. Jose E. GonzalezOTHER | 1 | Aug 10, 2017 | clinicaltrials |
| NCT00837200 | Oncaspar/Doxil/Decadron in Patients With Refractory Lymphoid Malignancies | terminated | Phase 2 | 13 | Milton S. Hershey Medical CenterOTHER | 1 | Jul 24, 2017 | clinicaltrials |
| NCT00072514 | Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies | completed | Phase 2 | 55 | Fred Hutchinson Cancer CenterOTHER | 1 | Jun 29, 2017 | clinicaltrials |
| NCT02408042 | Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme) | withdrawn | Phase 1 / Phase 2 | 0 | Western Regional Medical CenterOTHER | 1 | Jun 27, 2017 | clinicaltrials |
| NCT00388349 | Gemcitabine and Hodgkin's Disease Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Hodgkin's Disease | completed | Phase 2 | 146 | Stanford UniversityOTHER | 1 | Jun 14, 2017 | clinicaltrials |
| NCT00241358 | Study Evaluating AMD3100 for Transplantation of Sibling Donor Stem Cells in Patients With Hematological Malignancies | completed | Phase 1 / Phase 2 | 92 | Washington University School of MedicineOTHER | 1 | Jun 6, 2017 | clinicaltrials |
| NCT01158118 | Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donors | completed | Phase 2 | 48 | Washington University School of MedicineOTHER | 1 | Jun 5, 2017 | clinicaltrials |
| NCT01220297 | Sirolimus & Mycophenolate Mofetil as GvHD Prophylaxis in Myeloablative, Matched Related Donor HCT | terminated | Phase 2 | 3 | Stanford UniversityOTHER | 1 | Jun 5, 2017 | clinicaltrials |
| NCT00118352 | Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer | completed | Phase 2 | 12 | Fred Hutchinson Cancer CenterOTHER | 2 | May 30, 2017 | clinicaltrials |
| NCT00601718 | Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma | completed | Phase 1 / Phase 2 | 29 | University of WashingtonOTHER | 1 | May 25, 2017 | clinicaltrials |
| NCT01110135 | Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma | completed | Phase 2 | 43 | University of WashingtonOTHER | 1 | May 24, 2017 | clinicaltrials |
| NCT00795769 | Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant | completed | Phase 2 | 49 | Fred Hutchinson Cancer CenterOTHER | 1 | May 23, 2017 | clinicaltrials |
| NCT01427881 | Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies | completed | Phase 2 | 43 | Fred Hutchinson Cancer CenterOTHER | 1 | May 19, 2017 | clinicaltrials |
| NCT00049504 | Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer | completed | Phase 2 | 53 | Fred Hutchinson Cancer CenterOTHER | 1 | May 17, 2017 | clinicaltrials |
| NCT03044743 | PD-1 Knockout EBV-CTLs for Advanced Stage Epstein-Barr Virus (EBV) Associated Malignancies | unknown | Phase 1 / Phase 2 | 20 | Yang YangOTHER | 1 | May 2, 2017 | clinicaltrials |
| NCT00003820 | Rituximab in Treating Patients With Hodgkin's Lymphoma | completed | Phase 2 | 39 | Ranjana AdvaniOTHER | 1 | Apr 20, 2017 | clinicaltrials |
| NCT02200380 | A Safety and Tolerability Study of CDX-301 With or Without Plerixafor for Stem Cell Mobilization in Matched Related Allogeneic Donor/Recipient Sibling Transplant Pairs | terminated | Phase 2 | 36 | Celldex TherapeuticsINDUSTRY | 1 | Apr 7, 2017 | clinicaltrials |
| NCT00698685 | Pentostatin and Alemtuzumab as a Preparative Regimen for Allogeneic Peripheral Blood Stem Cell Transplantation | terminated | Phase 2 | 14 | University of ArizonaOTHER | 1 | Mar 31, 2017 | clinicaltrials |
| NCT00848926 | A Pivotal Open-Label Trial of Brentuximab Vedotin for Hodgkin Lymphoma | completed | Phase 2 | 102 | Seagen Inc.INDUSTRY | 5 | Mar 13, 2017 | clinicaltrials |
| NCT00733824 | Intravenous AMD3100 for Collection of Autologous Peripheral Blood Stem Cells in Patients With Lymphoma | completed | Phase 1 / Phase 2 | 61 | Washington University School of MedicineOTHER | 1 | Mar 9, 2017 | clinicaltrials |
| NCT01181271 | Tandem Auto-Allo Transplant for Lymphoma | completed | Phase 2 | 42 | Massachusetts General HospitalOTHER | 1 | Mar 9, 2017 | clinicaltrials |
| NCT00705250 | Bendamustine HCL in Relapsed and Primary Refractory Hodgkin Lymphoma | completed | Phase 2 | 36 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Mar 3, 2017 | clinicaltrials |
| NCT00460694 | Allogeneic Cytokine-induced Killer Immunotherapy for Relapse After Allogeneic Marrow Transplant for Haematological Malignancies(alloCIK) | completed | Phase 1 / Phase 2 | 24 | Singapore General HospitalOTHER | 1 | Feb 10, 2017 | clinicaltrials |
| NCT00947856 | A Brentuximab Vedotin Trial for Patients Who Have Previously Participated in a Brentuximab Vedotin Study | completed | Phase 2 | 110 | Seagen Inc.INDUSTRY | 2 | Feb 2, 2017 | clinicaltrials |
| NCT00683046 | T-Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Hematologic Malignancies | completed | Phase 2 | 204 | University of ChicagoOTHER | 1 | Nov 22, 2016 | clinicaltrials |
| NCT02115126 | Phase II Trial to Evaluate an EBV-derived Dendritic Cell Vaccine in Autologous Stem Cell Transplant | withdrawn | Phase 2 | 0 | David Rizzieri, MDOTHER | 1 | Nov 1, 2016 | clinicaltrials |
| NCT00025662 | Selective T-Cell Depletion to Reduce GVHD (Patients) Receiving Stem Cell Tx to Treat Leukemia, Lymphoma or MDS | completed | Phase 2 | 23 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Oct 28, 2016 | clinicaltrials |
| NCT01699581 | Assessment of Impact Nutritional Program During Autologous Stem Cell Transplant | terminated | Phase 2 | 35 | Greg MonohanOTHER | 1 | Oct 18, 2016 | clinicaltrials |
| NCT00112723 | Flavopiridol in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma | terminated | Phase 1 / Phase 2 | 46 | National Cancer Institute (NCI)NIH | 1 | Aug 8, 2016 | clinicaltrials |
| NCT01523847 | A Multi-centre Study of MBVD in Elderly and/or Cardiopathic Patients Affected by Hodgkin's Lymphoma (HL)(HD0803) | completed | Phase 2 | 50 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Aug 4, 2016 | clinicaltrials |
| NCT00133367 | Study of Unrelated Cord Blood Transplantation Using Tacrolimus and Sirolimus | completed | Phase 2 | 32 | Massachusetts General HospitalOTHER | 1 | Jul 25, 2016 | clinicaltrials |
| NCT00533923 | Nonmyeloablative Allogeneic Stem Cell Transplantation From HLA-Matched Unrelated Donor for the Treatment of Hematologic Disorders | completed | Phase 2 | 25 | Beth Israel Deaconess Medical CenterOTHER | 1 | Jul 18, 2016 | clinicaltrials |
| NCT01652014 | Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies | withdrawn | Phase 2 | 0 | University of Medicine and Dentistry of New JerseyOTHER | 1 | Jul 14, 2016 | clinicaltrials |
| NCT01079013 | Treosulfan-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid Malignancies | unknown | Phase 2 | 40 | Sheba Medical CenterOTHER_GOV | 1 | Apr 20, 2016 | clinicaltrials |
| NCT02507479 | Thiotepa-based Conditioning for Allogeneic Stem-cell Transplantation (SCT) in Lymphoid Malignancies | unknown | Phase 2 | 24 | Sheba Medical CenterOTHER_GOV | 1 | Apr 20, 2016 | clinicaltrials |
| NCT00975975 | Basiliximab #2: In-Vivo Activated T-Cell Depletion to Prevent Graft-Versus_Host Disease (GVHD) After Nonmyeloablative Allotransplantation for the Treatment of Blood Cancer | completed | Phase 2 | 17 | Indiana UniversityOTHER | 1 | Feb 26, 2016 | clinicaltrials |
| NCT01195766 | Study of Ofatumumab and ESHAP for the Treatment of Hodgkin's Lymphoma | completed | Phase 2 | 64 | Grupo Español de Linfomas y Transplante Autólogo de Médula ÓseaOTHER | 1 | Feb 24, 2016 | clinicaltrials |
| NCT02259556 | CD30-directed Chimeric Antigen Receptor T (CART30) Therapy in Relapsed and Refractory CD30 Positive Lymphomas(CART30) | recruiting | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Jan 28, 2016 | clinicaltrials |
| NCT01336712 | Total Body Irradiation/Fludarabine Based Ablative Haploidentical Transplant for Hematologic Diseases | completed | Phase 2 | 30 | Northside Hospital, Inc.OTHER | 1 | Jan 14, 2016 | clinicaltrials |
| NCT00163748 | Efficacy and Treatment Related Toxicity Study of a New Regimen for Lymphoma | completed | Phase 2 | 40 | Bayside HealthOTHER_GOV | 1 | Jan 8, 2016 | clinicaltrials |
| NCT00163761 | Efficacy Study of Outpatient Therapy for Lymphoma | completed | Phase 2 | 90 | Bayside HealthOTHER_GOV | 1 | Jan 8, 2016 | clinicaltrials |
| NCT00592111 | A Comprehensive Study of Clinically Staged Pediatric Hodgkin's Disease: Chemotherapy for All Patients; Supplementary Low Dose Involved Field Irradiation for Selected Patients (CCG 5942) | completed | Phase 2 | 21 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 23, 2015 | clinicaltrials |
| NCT00001575 | Anti-Tac(90 Y-HAT) to Treat Hodgkin's Disease, Non-Hodgkin's Lymphoma and Lymphoid Leukemia | completed | Phase 1 / Phase 2 | 87 | National Cancer Institute (NCI)NIH | 1 | Dec 7, 2015 | clinicaltrials |
Data updated 22 days agoSource updated Dec 6, 2017source: clinicaltrials